Adcentrx raises funds to advance ADCs into clinical development
2023-04-26
抗体药物偶联物临床1期
Preview
来源: Pharmaceutical Technology
Adcentrx is focused on developing protein conjugate therapeutics to treat cancer and other life-threatening diseases. Credit: National Cancer InstituteCancer Institute on Unsplash.
Biotechnology company Adcentrx Therapeutics has raised $38m in Series A+ financing to advance its pipeline of new antibody-drug conjugate (ADC) therapeutics into clinical development.
Lighthouse Capital and Life Venture Partners served as financial advisors to the company.
Recommended Reports
Preview
来源: Pharmaceutical Technology
ReportsVascular Endothelial Growth Factor (VEGF) Drugs in Development by Therapy Areas and Indications, ... GlobalData
Preview
来源: Pharmaceutical Technology
ReportsTransforming Growth Factor (TGF) Drugs in Development by Therapy Areas and Indications, Stages, M... GlobalData
View all
Led by Eight Roads Ventures, the financing round saw participation from strategic investors, including the Trinity Innovation Fund, ABio-X, Delta Capital and F-Prime Capital.
Adcentrx Therapeutics is focused on developing protein conjugate therapeutics to treat cancer and other life-threatening diseases.
It works to develop advanced targeted therapeutics to improve patient treatment options by combining the targeting precision of biologics and the small molecule payloads’ disease-fighting power.
ADRX-070 is the company’s lead candidate and is anticipated to enter a first-in-human Phase I clinical trial in the second half of 2023.
The company is developing other candidates and intends to advance at least one into clinical development each year.
Adcentrx Therapeutics founder and CEO Hui Li said: “Over the last two years, we have made significant progress advancing our emerging therapeutic pipeline that implements our proprietary and differentiated technology platform.
“This new round of funding from our investors will enable Adcentrx to quickly advance our safer and more efficacious conjugate therapies for patients in need.
“This year will be pivotal for Adcentrx, when we transition from the discovery stage into a clinical-stage company.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
药物
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。